AstraZeneca PLC (AZN,AZN.L,ZEG.DE,AZN.ST) said its Saphnelo - anifrolumab - has been approved in the European Union for subcutaneous self-administration as a pre-filled pen for adult patients with systemic lupus erythematosus on top of standard therapy. The approval by the European Commission follows the positive opinion from the CHMP and was based on the positive results from the Phase III TULIP-SC trial.
The company noted that the subcutaneous administration of Saphnelo is under regulatory review in several other countries around the world including the US and Japan.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.